Department of Oncology, Medical University, 12 Ogrodowa St., Bialystok, Poland.
Thromb Haemost. 2010 Jan;103(1):198-204. doi: 10.1160/TH09-06-0416. Epub 2009 Sep 30.
Activation of blood coagulation, a phenomenon frequently observed in breast and colon cancer patients, contributes to tumour progression. The principal initiator of blood coagulation activation in cancer patients is tissue factor (TF), while tissue factor pathway inhibitor (TFPI) is the main inhibitor of the TF-dependent pathway of blood coagulation. Previous immunohistochemical studies revealed no expression of TFPI in human cancer cells. The aim of the study was to evaluate the expression of TFPI protein and mRNA in breast and colon cancer tissues. A total of 108 cancer tissues (from primary tumours and metastatic lymph nodes) were obtained from 87 patients during surgical treatment. Immunohistochemical studies using a polyclonal anti-TFPI antibody were performed including a semiquantitative analysis. The in situ hybridisation method employed single-stranded DNA oligonucleotide (probe sequence: 5'Biotin-CCACCATACTTGAAACGTTCACACT-Biotin3') directed against TFPI mRNA. Strong or medium expression of TFPI protein was observed in cancer cell bodies in all breast cancers and in most (39/66 cases) colon cancers examined. Weaker expression of TFPI was detected in cancer cells localised in lymph node metastatic foci of breast cancer. Endothelial cells were also TFPI-positive. TFPI mRNA was demonstrated in all cases of breast and in approximately 80% cases of colon cancer cells. TFPI mRNA and protein are present in association with colon and breast cancer cells, suggesting that the protein may play a role in cancer biology. The presence of TFPI in association with breast cancer cells localised in regional lymph nodes may indicate its role in lymphatic spread.
血液凝固的激活，这是在乳腺癌和结肠癌患者中经常观察到的现象，有助于肿瘤的进展。在癌症患者中，血液凝固激活的主要启动子是组织因子（TF），而组织因子途径抑制剂（TFPI）是 TF 依赖性血液凝固途径的主要抑制剂。以前的免疫组织化学研究表明，TFPI 在人类癌细胞中没有表达。本研究旨在评估 TFPI 蛋白和 mRNA 在乳腺癌和结肠癌组织中的表达。在手术治疗期间，从 87 名患者中获得了总共 108 个癌症组织（来自原发肿瘤和转移性淋巴结）。使用多克隆抗 TFPI 抗体进行了免疫组织化学研究，包括半定量分析。使用单链 DNA 寡核苷酸（探针序列：5'Biotin-CCACCATACTTGAAACGTTCACACT-Biotin3'）的原位杂交方法针对 TFPI mRNA。在所有乳腺癌和大多数（39/66 例）结肠癌中，都观察到癌细胞体中 TFPI 蛋白的强或中等表达。在乳腺癌淋巴结转移灶中定位的癌细胞中检测到较弱的 TFPI 表达。内皮细胞也是 TFPI 阳性的。在所有乳腺癌病例和大约 80%的结肠癌病例中都检测到 TFPI mRNA。TFPI mRNA 和蛋白与结肠和乳腺癌细胞共存，表明该蛋白可能在癌症生物学中发挥作用。TFPI 与定位在局部淋巴结中的乳腺癌细胞共存，可能表明其在淋巴扩散中的作用。
